Accord Adds To Oncology Offering With Orgovyx
Deal For Prostate Cancer Drug Follows Camcevi Leuprolide Launch In US
Accord Healthcare has struck a European licensing deal with Myovant Sciences for its Orgovyx (relugolix) treatment for advanced hormone-sensitive prostate cancer. The move comes shortly after sister company Accord Biopharma launched the Camcevi (leuprolide) prostate cancer treatment in the US.
